SLC16A1 and prostate cancer: While one study reported an increase of both MCT1 and MCT 4 expression and a positive correlation with prostate cancer progression [90], another report demonstrated a dramatic upregulation of both MCT 2 and MCT4, but a significant decrease in MCT1 expression in prostate cancer cells [91].